MedTrace Logo

Cost Effectiveness Of Sunitinib In Central America And Caribbean

NCT01033981 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2012-04-19

No results posted yet for this study

Summary

Primary Hypothesis: The therapy with Sunitinib represents better cost-effectiveness than IFN-α in first-line treatment for metastatic Renal Cell Carcinoma (mRCC) in Central America and Caribbean countries

Conditions

  • Metastatic Renal Cell Carcinoma

Interventions

DRUG

Sunitinib

Treatment for mRCC as indication approved and physician criterium

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Panama

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01033981 on ClinicalTrials.gov